29,982 Shares in Roivant Sciences Ltd. $ROIV Purchased by Inspire Investing LLC

Inspire Investing LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 29,982 shares of the company’s stock, valued at approximately $303,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of ROIV. Parallel Advisors LLC raised its holdings in Roivant Sciences by 80.5% during the 1st quarter. Parallel Advisors LLC now owns 2,485 shares of the company’s stock worth $25,000 after buying an additional 1,108 shares during the period. UMB Bank n.a. raised its holdings in Roivant Sciences by 112.7% during the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company’s stock worth $42,000 after buying an additional 2,195 shares during the period. Russell Investments Group Ltd. raised its holdings in Roivant Sciences by 94.8% during the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock worth $46,000 after buying an additional 2,233 shares during the period. Fifth Third Bancorp raised its holdings in Roivant Sciences by 59.3% during the 1st quarter. Fifth Third Bancorp now owns 5,118 shares of the company’s stock worth $52,000 after buying an additional 1,905 shares during the period. Finally, GAMMA Investing LLC raised its holdings in Roivant Sciences by 83.0% during the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company’s stock worth $66,000 after buying an additional 2,945 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Matthew Gline purchased 3,315 shares of Roivant Sciences stock in a transaction on Thursday, September 18th. The shares were purchased at an average price of $15.07 per share, for a total transaction of $49,957.05. Following the transaction, the chief executive officer owned 17,287,081 shares of the company’s stock, valued at approximately $260,516,310.67. This represents a 0.02% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Vivek Ramaswamy sold 1,195,000 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $12.50, for a total value of $14,937,500.00. Following the completion of the sale, the insider owned 36,089,108 shares in the company, valued at $451,113,850. This trade represents a 3.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,975,749 shares of company stock valued at $24,780,210 in the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Performance

Roivant Sciences stock opened at $15.09 on Friday. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $16.05. The stock has a market capitalization of $10.30 billion, a P/E ratio of -21.56 and a beta of 1.15. The stock has a fifty day moving average of $12.14 and a 200-day moving average of $11.25.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ROIV. JPMorgan Chase & Co. upped their target price on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday. The Goldman Sachs Group upped their target price on Roivant Sciences from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday. Bank of America increased their price objective on Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a research note on Thursday. Citigroup restated a “neutral” rating on shares of Roivant Sciences in a research note on Thursday. Finally, Guggenheim raised their price target on Roivant Sciences from $15.00 to $21.00 and gave the company a “buy” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.94.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.